Table 3.

Characteristics of studies from four Asian countries

	Number of study groups	Median sampling year (range)	Mean time since scale-up (years [range])	Weighted prevalence of drug-resistance mutations (95% CI)
Thailand	12	2005 (2000–09)	4·3 (0·5–9·0)	0·5% (0·1–1·4)
China	15	2006 (2001–10)	4·0 (0–7·5)	2·6% (1·4–4·1)
India	10	2007 (1999–10)	2·7 (0–6·0)	2·7% (1·1–4·7)
Vietnam	9	2008 (2006–09)	2·5 (1·0–4·0)	4·5% (3·3–6·0)

Data are given for only those countries with five or more studies. Not included in this table are Indonesia (n=1) and Cambodia (n=3).